Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. more
Time Frame | NVCR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.02% | -1.95% | 0.69% |
1-Month Return | 57.5% | -3.36% | 1.53% |
3-Month Return | 72.49% | -6.93% | 11.27% |
6-Month Return | 33.5% | -1.83% | 13.49% |
1-Year Return | 132.74% | 8.53% | 31.62% |
3-Year Return | -67.36% | 7.58% | 30.33% |
5-Year Return | -64.76% | 44.7% | 93.83% |
10-Year Return | 56.73% | 103.96% | 195.13% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 351.32M | 494.37M | 535.03M | 537.84M | 509.34M | [{"date":"2019-12-31","value":65.32,"profit":true},{"date":"2020-12-31","value":91.92,"profit":true},{"date":"2021-12-31","value":99.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.7,"profit":true}] |
Cost of Revenue | 88.61M | 106.50M | 114.88M | 114.87M | 128.28M | [{"date":"2019-12-31","value":69.07,"profit":true},{"date":"2020-12-31","value":83.02,"profit":true},{"date":"2021-12-31","value":89.55,"profit":true},{"date":"2022-12-31","value":89.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 262.71M | 387.87M | 420.15M | 422.97M | 381.06M | [{"date":"2019-12-31","value":62.11,"profit":true},{"date":"2020-12-31","value":91.7,"profit":true},{"date":"2021-12-31","value":99.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":90.09,"profit":true}] |
Gross Margin | 74.78% | 78.46% | 78.53% | 78.64% | 74.81% | [{"date":"2019-12-31","value":95.09,"profit":true},{"date":"2020-12-31","value":99.76,"profit":true},{"date":"2021-12-31","value":99.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":95.13,"profit":true}] |
Operating Expenses | 263.63M | 357.46M | 464.49M | 512.50M | 613.93M | [{"date":"2019-12-31","value":42.94,"profit":true},{"date":"2020-12-31","value":58.23,"profit":true},{"date":"2021-12-31","value":75.66,"profit":true},{"date":"2022-12-31","value":83.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (914.00K) | 21.25M | (44.33M) | (89.52M) | (232.87M) | [{"date":"2019-12-31","value":-4.3,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-208.62,"profit":false},{"date":"2022-12-31","value":-421.26,"profit":false},{"date":"2023-12-31","value":-1095.81,"profit":false}] |
Total Non-Operating Income/Expense | (15.39M) | (27.25M) | (11.45M) | 18.88M | 83.06M | [{"date":"2019-12-31","value":-18.53,"profit":false},{"date":"2020-12-31","value":-32.8,"profit":false},{"date":"2021-12-31","value":-13.79,"profit":false},{"date":"2022-12-31","value":22.73,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (8.82M) | 18.10M | (52.08M) | (81.85M) | (191.74M) | [{"date":"2019-12-31","value":-48.75,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-287.68,"profit":false},{"date":"2022-12-31","value":-452.14,"profit":false},{"date":"2023-12-31","value":-1059.22,"profit":false}] |
Income Taxes | (1.59M) | (1.71M) | 6.28M | 10.69M | 15.30M | [{"date":"2019-12-31","value":-10.42,"profit":false},{"date":"2020-12-31","value":-11.15,"profit":false},{"date":"2021-12-31","value":41.01,"profit":true},{"date":"2022-12-31","value":69.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (7.23M) | 19.81M | (58.35M) | (92.53M) | (207.04M) | [{"date":"2019-12-31","value":-36.5,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-294.58,"profit":false},{"date":"2022-12-31","value":-467.15,"profit":false},{"date":"2023-12-31","value":-1045.25,"profit":false}] |
Income From Continuous Operations | (7.23M) | 19.81M | (58.35M) | (92.53M) | (207.04M) | [{"date":"2019-12-31","value":-36.5,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-294.58,"profit":false},{"date":"2022-12-31","value":-467.15,"profit":false},{"date":"2023-12-31","value":-1045.25,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.23M) | 19.81M | (58.35M) | (92.53M) | (207.04M) | [{"date":"2019-12-31","value":-36.5,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-294.58,"profit":false},{"date":"2022-12-31","value":-467.15,"profit":false},{"date":"2023-12-31","value":-1045.25,"profit":false}] |
EPS (Diluted) | (0.08) | 0.19 | (0.56) | (0.88) | (1.95) | [{"date":"2019-12-31","value":-42.11,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-294.74,"profit":false},{"date":"2022-12-31","value":-463.16,"profit":false},{"date":"2023-12-31","value":-1026.32,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NVCR | |
---|---|
Cash Ratio | 1.31 |
Current Ratio | 1.49 |
Quick Ratio | 1.44 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NVCR | |
---|---|
ROA (LTM) | -7.93% |
ROE (LTM) | -39.71% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NVCR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.70 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.30 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NVCR | |
---|---|
Trailing PE | NM |
Forward PE | 909.09 |
P/S (TTM) | 5.24 |
P/B | 8.39 |
Price/FCF | NM |
EV/R | 4.74 |
EV/Ebitda | NM |
PEG | NM |
Novocure Ltd (NVCR) share price today is $28.65
Yes, Indians can buy shares of Novocure Ltd (NVCR) on Vested. To buy Novocure Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NVCR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Novocure Ltd (NVCR) via the Vested app. You can start investing in Novocure Ltd (NVCR) with a minimum investment of $1.
You can invest in shares of Novocure Ltd (NVCR) via Vested in three simple steps:
The 52-week high price of Novocure Ltd (NVCR) is $32.6. The 52-week low price of Novocure Ltd (NVCR) is $11.66.
The price-to-earnings (P/E) ratio of Novocure Ltd (NVCR) is
The price-to-book (P/B) ratio of Novocure Ltd (NVCR) is 8.39
The dividend yield of Novocure Ltd (NVCR) is 0.00%
The market capitalization of Novocure Ltd (NVCR) is $3.03B
The stock symbol (or ticker) of Novocure Ltd is NVCR